Clinical Trials Using Alemtuzumab

Clinical trials are research studies that involve people. The clinical trials on this list are studying Alemtuzumab. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-9 of 9
  • Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita

    Dyskeratosis congenita is a disease that affects numerous parts of the body, most typically causing failure of the blood system. Lung disease, liver disease and cancer are other frequent causes of illness and death. Bone marrow transplantation (BMT) can cure the blood system but can make the lung and liver disease and risk of cancer worse, because of DNA damaging agents such as alkylators and radiation that are typically used in the procedure. Based on the biology of DC, we hypothesize that it may be possible to avoid these DNA damaging agents in patients with DC, and still have a successful BMT. In this protocol we will test whether a regimen that avoids DNA alkylators and radiation can permit successful BMT without compromising survival in patients with DC.
    Location: 5 locations

  • Allogeneic Hematopoietic Stem Cell Transplant for People With Primary Immunodeficiency Diseases

    Background: During a transplant, blood stem cells from one person are given to someone else. The cells grow into the different cells that make up the immune system. This can cure people with certain immunodeficiencies. But transplant has many risks and complications. Objective: To see if stem cell transplant can be successfully performed in people with primary immunodeficiency disease and cure them. Eligibility: People ages 4-69 for whom a primary immunodeficiency (PID) or Primary Immune Regulatory Disorder (PIRD), has caused significant health problems and either standard management has not worked or there are no standard management options, along with their donors Design: Donors will be screened under protocol 01-C-0129. They will donate blood or bone marrow. Participants will be screened with: Medical history Physical exam Blood, urine, and heart tests CT or PET scans Before transplant, participants will have dental and eye exams. They will have a bone marrow biopsy. For this, a needle will be inserted through the skin into the pelvis to remove marrow. Participants will be hospitalized before their transplant. They will have a central catheter put into a vein in their chest or neck. They will get medications through the catheter to prevent complications. Participants will get stem cells through the catheter. They will stay in the hospital for at least 4 weeks. They will give blood, urine, bone marrow, and stool samples. They may need blood transfusions. They may need more scans. They will take more medications. Participants will have visits on days 30, 60, 100, 180, and 360, and 24 months after the transplant. Then they will have visits once a year for about 5 years
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland

  • Itacitinib and Alemtuzumab in Treating Patients with T-Cell Prolymphocytic Leukemia

    This phase Ib trial studies the side effects and best dose of alemtuzumab when given together with itacitinib in treating patients with T-cell prolymphocytic leukemia. Itacitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with alemtuzumab, may induce changes in body’s immune system and may interfere with the ability of tumor cells to grow and spread. Giving itacitinib and alemtuzumab may work better in treating patients with T-cell prolymphocytic leukemia compared to standard of care treatment.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Myeloablative or Reduced-Intensity Conditioning Regimen in Treating Patients with High-Risk, Relapsed, or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Donor Stem Cell Transplant

    This phase II trial studies the side effects and how well a myeloablative or reduced-intensity conditioning regimen works in treating patients with acute myeloid leukemia or myelodysplastic syndrome that is high-risk, has come back, or does not respond to treatment. Giving chemotherapy (myeloablative or reduced-intensity conditioning regimen) before a donor peripheral blood stem cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. When healthy stem cells from a donor that have been genetically modified are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells (called graft-versus-host disease). Giving tacrolimus or cyclosporine after the transplant may stop this from happening. It is not yet known whether myeloablative or reduced-intensity conditioning regimens given before the transplant will work better in treating patients with acute myeloid leukemia or myelodysplastic syndrome.
    Location: Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania

  • Alemtuzumab or Tocilizumab in Combination with Etoposide and Dexamethasone in Treating Patients with Hemophagocytic Lymphohistiocytosis

    This phase II trial studies how well alemtuzumab or tocilizumab in combination with etoposide and dexamethasone work in treating patients with hemophagocytic lymphohistiocytosis. Hemophagocytic lymphohistiocytosis is a disorder that causes abnormal over activity of the immune system. Immunosuppressive therapy, using drugs such as alemtuzumab, tocilizumab, etoposide, and dexamethasone, may decrease the body’s immune system activity and prevent the immune system from causing damage to organs.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Nonmyeloablative Donor Stem Cell Transplant in Treating Patients with Congenital Anemias including Sickle Cell Disease and Thalassemia

    This phase II trial studies the safety and efficacy of a nonmyeloablative (bone marrow will not be completely destroyed) donor stem cell transplant in treating patients with congenital (condition or trait present at birth) anemias including sickle cell disease and thalassemia. Giving low doses of total-body irradiation before a donor stem cell transplant may help stop the growth of abnormal cells. It may also stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining abnormal cells. Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving immunosuppressive therapies, such as alemtuzumab and sirolimus, before transplant may stop this from happening.
    Location: UT Southwestern / Simmons Cancer Center-Dallas, Dallas, Texas

  • Reduced Intensity Conditioning Regimen for the Treatment of Non-Malignant Disorders

    This phase II trial studies how well a reduced intensity conditioning regimen works in treating patients with non-cancer (non-malignant) disorders. Reduced intensity conditioning involves giving medicines that suppress the immune system before giving the donor stem cells. It does not completely eliminate the blood making cells in bone marrow. Giving a reduced intensity conditioning regimen may result in fewer short and long term side effects, shorter hospital stay than after conditioning that completely destroys the bone marrow, and blood counts may recover more quickly.
    Location: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

  • Best Available Therapy Versus Autologous Hematopoetic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)

    This is a multi-center prospective rater-masked (blinded) randomized controlled trial of 156 participants, comparing the treatment strategy of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) to the treatment strategy of Best Available Therapy (BAT) for treatment-resistant relapsing multiple sclerosis (MS). Participants will be randomized at a 1 to 1 (1:1) ratio. All participants will be followed for 72 months after randomization (Day 0, Visit 0).
    Location: 2 locations

  • Microdevice for In Situ Candidate Drug Screening in Skin Lesions of T-Cell Lymphoma

    This pilot trial studies the side effects and feasibility of microdevice for in situ candidate drug screening in skin lesions of T-cell lymphoma. Implanting and retrieving a microdevice that releases up to 19 drugs directly within a skin lesion may be a possible tool to evaluate the effectiveness of several approved cancer drugs against cutaneous T cell lymphoma or peripheral T cell lymphoma.
    Location: 2 locations